The American College of Cardiology has released a new scientific statement consolidating antiplatelet therapy recommendations across both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Rather than replacing existing condition-specific guidelines, it serves as a unified reference comparing American and European guidance. A key takeaway: shorter DAPT durations are now considered safe for many ACS and PCI patients.
The American College of Cardiology (ACC) has published a new scientific statement in the Journal of the American College of Cardiology that consolidates antiplatelet therapy recommendations across the full spectrum of atherosclerotic cardiovascular disease (ASCVD) — from primary prevention to acute and chronic coronary syndromes. Rather than replacing existing condition-specific guidelines, the document acts as a "one-stop-shop" comparison of major American and European guidance, helping clinicians navigate patients who transition across disease phases or carry overlapping conditions.
The statement highlights both areas of agreement and divergence between U.S. and European guidelines. For instance, both sides align on 12 months of dual antiplatelet therapy (DAPT) as the default post-ACS strategy, but differ on drug preference — European guidelines favor prasugrel over ticagrelor after PCI, while U.S. guidelines make no such distinction.
Key Takeaways:
Why it matters: With multiple overlapping guidelines in circulation, this consolidated reference gives clinicians a clearer, more practical framework for tailoring antiplatelet decisions across the entire ASCVD continuum.
